Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred Saad

Showing results (871-880 of 993) with videos related to

Pageof 100
Sort By:
Annals of Surgical Oncology|July 20, 2024
Adjuvant Systemic Therapy Improved Survival After Radical Nephroureterectomy for Upper Tract Urothelial CarcinomaFrancesco Di Bello, Letizia Maria Ippolita Jannello, Carolin Siech, et al.
Lancet (London, England)|July 19, 2025
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trialNeeraj Agarwal, Arun A Azad, Joan Carles, et al.
Annals of Surgical Oncology|May 27, 2025
Cancer-Specific Mortality of Partial Cystectomy Versus Radical Cystectomy in T2N0M0 Urothelial Bladder CancerMattia Longoni, Andrea Marmiroli, Fabian Falkenbach, et al.
Annals of Surgical Oncology|May 2, 2025
Comparison of In-Hospital Outcomes at Robot-Assisted Versus Open Partial NephrectomyFrancesco Di Bello, Natali Rodriguez Penaranda, Andrea Marmiroli, et al.
Japanese Journal of Clinical Oncology|February 18, 2024
A population-based validation of the IGCCCG Update Consortium for survival in metastatic non-seminoma testis cancerReha-Baris Incesu, Simone Morra, Lukas Scheipner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2023
Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in <i>BRCA1</i> and/or <i>BRCA2</i> in the PROfound TrialJoaquin Mateo, Johann S de Bono, Karim Fizazi, et al.
Journal of Managed Care & Specialty Pharmacy|July 5, 2023
Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defectsMatthew R Smith, Shahneen Sandhu, Daniel J George, et al.
European Urology|August 2, 2016
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL StudyTomasz M Beer, Andrew J Armstrong, Dana Rathkopf, et al.
BJUI Compass|August 11, 2022
Patterns of care for non-metastatic castration-resistant prostate cancer: A population-based studyShawn Malone, Christopher J D Wallis, Richard Lee-Ying, et al.
Annals of Surgical Oncology|May 17, 2026
Years of Life Lost in Patients with Muscle-Invasive and Metastatic Bladder CancerMattia Longoni, Fabian Falkenbach, Andrea Marmiroli, et al.
Pageof 100

Showing results (871-880 of 993) with videos related to

Sort By:
Pageof 100
Annals of Surgical Oncology|July 20, 2024
Adjuvant Systemic Therapy Improved Survival After Radical Nephroureterectomy for Upper Tract Urothelial CarcinomaFrancesco Di Bello, Letizia Maria Ippolita Jannello, Carolin Siech, et al.
Lancet (London, England)|July 19, 2025
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trialNeeraj Agarwal, Arun A Azad, Joan Carles, et al.
Annals of Surgical Oncology|May 27, 2025
Cancer-Specific Mortality of Partial Cystectomy Versus Radical Cystectomy in T2N0M0 Urothelial Bladder CancerMattia Longoni, Andrea Marmiroli, Fabian Falkenbach, et al.
Annals of Surgical Oncology|May 2, 2025
Comparison of In-Hospital Outcomes at Robot-Assisted Versus Open Partial NephrectomyFrancesco Di Bello, Natali Rodriguez Penaranda, Andrea Marmiroli, et al.
Japanese Journal of Clinical Oncology|February 18, 2024
A population-based validation of the IGCCCG Update Consortium for survival in metastatic non-seminoma testis cancerReha-Baris Incesu, Simone Morra, Lukas Scheipner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2023
Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in <i>BRCA1</i> and/or <i>BRCA2</i> in the PROfound TrialJoaquin Mateo, Johann S de Bono, Karim Fizazi, et al.
Journal of Managed Care & Specialty Pharmacy|July 5, 2023
Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defectsMatthew R Smith, Shahneen Sandhu, Daniel J George, et al.
European Urology|August 2, 2016
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL StudyTomasz M Beer, Andrew J Armstrong, Dana Rathkopf, et al.
BJUI Compass|August 11, 2022
Patterns of care for non-metastatic castration-resistant prostate cancer: A population-based studyShawn Malone, Christopher J D Wallis, Richard Lee-Ying, et al.
Annals of Surgical Oncology|May 17, 2026
Years of Life Lost in Patients with Muscle-Invasive and Metastatic Bladder CancerMattia Longoni, Fabian Falkenbach, Andrea Marmiroli, et al.
Pageof 100